Physician profile
Bobbie S Pearson
NPI 1740552439
$451.55
in general payments reported to CMS, 2019-2025
13 companies · $40.00 in 2025
The $40.00 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $28.12 · 2024: $213 · 2025: $40.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $100.82 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $89.90 | 2021-2025 | Farxiga, Fasenra |
| Ibsa Pharma INC. | $42.53 | 2024-2025 | Tirosint, Licart, Flector |
| Corcept Therapeutics | $36.79 | 2024 | Korlym |
| Exact Sciences Corporation | $29.74 | 2024 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $28.12 | 2022 | |
| Novo Nordisk INC | $22.47 | 2021 | |
| Pfizer INC. | $20.46 | 2024 | |
| Aimmune Therapeutics, INC. | $17.97 | 2024 | |
| Amgen INC. | $17.38 | 2024 | Evenity |
| Genentech USA, INC. | $16.17 | 2021 | |
| Neos Therapeutics, LP | $15.41 | 2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $13.79 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobbie Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.